PMEL and melanoma: The gp100 epitope was previously shown to establish a strong immunotherapeutic response in murine melanoma models, which can be further enhanced by delivery on a modified VLP, thus, providing a means of evaluating the immunogenicity of the dry formulated VLP [41].